AMT-116 in Patients With Advanced Solid Tumors

Advanced Solid Tumor Clinical Trial

Official title:

First-in-Human, Phase 1 Study of AMT-116 in Patients With Advanced Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05725291
• Other study ID #: AMT-116-01
• Status: Recruiting
• Phase: Phase 1
• Start date: June 28, 2023
• Est. completion date: July 30, 2025

Study information

• Verified date: July 2023
• Source: Multitude Therapeutics Inc.
• Contact: Shuang Leng
• Phone: +61 411818616
• Email: shuang.leng[@]multitudetherapeutics.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-116, in Patients with Advanced Solid Tumors

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 48
• Est. completion date: July 30, 2025
• Est. primary completion date: January 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Key Inclusion Criteria:

• Patients must be willing and able to sign the ICF, and to adhere to the study visit schedule and other protocol requirements.

• Age =18 years (at the time consent is obtained).

• Patients with histologically confirmed, unresectable advanced solid tumor. Preferred tumor types include head and neck, non-small cell lung, esophageal, pancreatic, large cell lung, colorectal, cervical, breast, bladder, gastric, biliary tract, skin squamous cell, liver, and basal cell cancer.

• Patients who have undergone at least one systemic therapy and have radiologically or clinically determined progressive disease during or after most recent line of therapy, and for whom no further standard therapy is available, or who are intolerable to standard therapy.

• Patients must have at least one measurable lesion as per RECIST version 1.1.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

• Both male and female patients must agree to use effective contraceptive methods.

• Patients must have adequate organ function.

• Women of child-bearing potential (WCBP) must have a negative serum pregnancy test.

• Male patients must agree to use a latex condom, even if they had a successful vasectomy, while on study treatment and for at least 12 weeks after the last dose of the IMP.

• Male patients must agree not to donate sperm, and female patients must agree not to donate eggs, while on study treatment and for at least 12 weeks after the last dose of the IMP.

• Availability of tumour tissue sample (either an archival specimen or a fresh biopsy material) at screening.

Key Exclusion Criteria:

• Prior therapy with ADC based on Top1 inhibitor.

• Central nervous system (CNS) metastasis.

• Active or chronic skin disorder requiring systemic therapy.

• History of Steven's Johnson's syndrome or Toxic Epidermal Necrolysis syndrome.

• Active ocular conditions requiring treatment or close monitoring, including, but not limited to: macular degeneration, papilledema, active diabetic retinopathy with macular oedema, wet age-related macular degeneration requiring intravitreal injections, or uncontrolled glaucoma.

• Persistent toxicities from previous systemic anti-neoplastic treatments of Grade >1.

• Systemic anti-neoplastic therapy within five half-lives or 21 days, whichever is shorter, prior to first dose of the IMP.

• Radiotherapy to lung field at a total radiation dose of =20 Gy within 6 months, wide-field radiotherapy (e.g., > 30% of marrow-bearing bones) within 28 days.

• Major surgery (not including placement of vascular access device or tumor biopsies) within 28 days prior to the first dose of the IMP, or no recovery from side effects of such intervention.

• Prior allogeneic or autologous bone marrow transplantation.

• Significant cardiac disease, such as recent (within six months prior to first dose of the IMP) myocardial infarction or acute coronary syndromes (including unstable angina pectoris), congestive heart failure (New York Heart Association class III or IV), uncontrolled hypertension, uncontrolled cardiac arrhythmias.

• Pregnant or breast-feeding females.

Note: Other protocol defined Inclusion/Exclusion criteria apply.

Related Conditions & MeSH terms

• Advanced Solid Tumor
• Neoplasms

Intervention

Drug:
• AMT-116
Administered intravenously

Locations

Country	Name	City	State
Australia	ICON Cancer Centre	Brisbane	Queensland

Sponsors (1)

Lead Sponsor	Collaborator
Multitude Therapeutics Inc.

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Recommended Phase 2 Dose (RP2D)	The RP2D will be determined using dose limiting toxicities (DLTs) and all other available study data	Up to 24 months
Primary	Maximum Tolerated Dose (MTD)	The MTD will be determined using DLTs	Up to 24 months
Primary	Type, incidence and severity of Adverse Events	Safety and tolerability profile assessed by the Common Terminology Criteria for Adverse Events v5.0	Up to 24 months
Secondary	Overall Response Rate (ORR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1	Proportion of patients achieving Complete Response (CR) or Partial Response (PR)	Up to 24 months
Secondary	Disease Control Rate (DCR) according to the RECIST v1.1	Proportion of patients achieving CR, PR or Stable Disease (SD)	Up to 24 months
Secondary	Progression-free Survival (PFS)	Time from date of start of treatment to date of the first progression or death, whichever occurs first.	Up to 24 months
Secondary	Concentration of anti-drug antibodies (ADA)	Immunogenicity profile characterized by concentration of ADAs	Up to 24 months
Secondary	Maximum observed concentration (C[max])	Pharmacokinetic profile characterized by the maximum observed concentration (C[max]) of AMT-116	Up to 24 months
Secondary	Area under the curve (AUC)	Pharmacokinetic profile characterized by the area under the curve (AUC) of AMT-116	Up to 24 months
Secondary	Terminal half-life (t[1/2])	Pharmacokinetic profile characterized by the terminal half-life (t[1/2]) of AMT-116	Up to 24 months
Secondary	Time to maximum concentration (Tmax)	Pharmacokinetic profile characterized by the time to maximum concentration (Tmax) of AMT-116	Up to 24 months